Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients
Frontiers in Oncology · 26.01.2023 · 12
DOI: 10.3389/fonc.2022.1055968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 26.01.2023. Verfasst von Hiu Ting Chan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Project for Development of Liquid Biopsy Diagnosis, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Biomedical Innovation, Health and Nutrition.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Circulating tumor DNA (ctDNA) has been increasingly recognized as a promising minimally-invasive biomarker that could identify patients with minimal residual disease and a high risk of recurrence after definitive treatment. In this study, we’ve compared the clinical utility and sensitivity of 2 different approaches to ctDNA analyses: tumor-informed and tumor-agnostic in the management of colorectal (CRC) patients. The clinical benefits of a single timepoint ctDNA analysis compared to serial ctDNA monitoring after definitive treatment were also evaluated to uncover the ideal surveillance protocol.
Methods
Patient-paired resected tumor tissues, peripheral blood cells, and a total of 127 pre-operative and serial plasma cell-free DNA (cfDNA) samples after definitive treatment from 38 CRC patients that had undergone curative intent surgery were analyzed using a commercial NGS cfDNA panel.
Results
Up to 84% (32/38) of the recruited patients were detected with at least 1 genomic alteration from the tumor tissues that could be monitored using the tumor-informed ctDNA approach and none of the detected alterations were clonal hematopoiesis (CH) related. In contrast, 37% (14/38) of patients were detected with at least 1 monitoring alteration after exclusion of CH mutations using the tumor-agnostic approach. Serial plasma samples after definitive therapy were available for 31 patients. In the landmark ctDNA analysis, 24% (7/29) of patients had detectable ctDNA and were more likely to relapse than ctDNA-negative patients (p < 0.05). The landmark analysis sensitivity and specificity for recurrence were 67% and 87%, respectively. The incorporation of longitudinal ctDNA analysis at 6-months intervals improved the sensitivity to 100%. The median variant allele frequency (VAF) of the ctDNA mutations detected during surveillance was 0.028% (range: 0.018-0.783), where up to 80% (8/10) of the mutations were detected at VAF lower than the tumor-agnostic detection limit of 0.1%. Utilizing the tumor-agnostic approach reduced the recurrence detection sensitivity to 67% (4/6). Serial ctDNA analyses predicted disease recurrence at a median of 5 months ahead of radiological imaging.
Conclusion
Longitudinal monitoring using tumor-informed ctDNA testing shows high analytical sensitivity, low probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence which may modify the clinical management of CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Project for Development of Liquid Biopsy Diagnosis, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Gastroenterological and Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Surgery, Uji-Tokushukai Medical Center, Kyoto, Japan.
- Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Research and Development, Cancer Precision Medicine, Inc., Kawasaki, Japan.
Förderung
- National Institutes of Biomedical Innovation, Health and Nutrition
Zitieren
APA
Chan, H. T., Nagayama, S., Otaki, M., Chin, Y. M., Fukunaga, Y., Ueno, M., Nakamura, Y., & Low, S. K. (2023). Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1055968
Vancouver
Chan HT, Nagayama S, Otaki M, Chin YM, Fukunaga Y, Ueno M, et al. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1055968
BibTeX
@article{Chan2023,
author = {Chan, Hiu Ting and Nagayama, Satoshi and Otaki, Masumi and Chin, Yoon Ming and Fukunaga, Yosuke and Ueno, Masashi and Nakamura, Yusuke and Low, Siew-Kee},
title = {Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients},
journal = {Frontiers in Oncology},
year = {2023},
volume = {12},
doi = {10.3389/fonc.2022.1055968}
}
EUVIMED